3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Theralase Technologies's 3-Year ROIIC % for the quarter that ended in Dec. 2024 was 37.46%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Theralase Technologies's 3-Year ROIIC % or its related term are showing as below:
TSXV:TLT's 3-Year ROIIC % is ranked better than 78.48% of 818
companies
in the Medical Devices & Instruments industry
Industry Median: 0.02
vs TSXV:TLT: 37.46
Theralase Technologies 3-Year ROIIC % Historical Data
The historical data trend for Theralase Technologies's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Theralase Technologies's 3-Year ROIIC %
For the Medical Devices subindustry, Theralase Technologies's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theralase Technologies's 3-Year ROIIC % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Theralase Technologies's 3-Year ROIIC % falls into.
Theralase Technologies 3-Year ROIIC % Calculation
Theralase Technologies's 3-Year ROIIC % for the quarter that ended in Dec. 2024 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -4.288 (Dec. 2024) - -4.542 (Dec. 2021) )
/
( 2.092 (Dec. 2024) - 1.414 (Dec. 2021) )
=
0.254
/
0.678
=
37.46%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Theralase Technologies 3-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Theralase Technologies's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:TLT has been successfully added to your 